P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.608
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

Frontiers in Oncology
Cancer ResearchOncology
2016English

192TiP: NEPTUNE: A Global, Phase 3 Study of Durvalumab (MEDI4736) Plus Tremelimumab Combination Therapy Versus Standard of Care (SoC) Platinum-Based Chemotherapy in the First-Line Treatment of Patients (Pts) With Advanced or Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2020English

PD.1.01 Health-Related Quality of Life With Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy